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between both groups was 4,9% (p = 0.19). CONCLU-
SIONS: Self-measurement of blood pressure has demon-
strated its effectiveness in the control of blood pressure
in hypertensive patients at short term, although its effec-
tiveness is reduced after some time.
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OBJECTIVES: To study the determinants and effective-
ness of lipid-lowering drugs with respect to lowering of
cholesterol levels in routine daily practice. METHODS:
Setting: Patient level data were obtained for all citizens
who ever lived in the period 1991–2001 in a city in the
centre of the country (N = 97,500) as part of 24 cities of
the PHARMO system. Data included per patient mea-
surements of plasma lipid levels (total cholesterol, low
density lipoprotein cholesterol, high density lipoprotein,
triglycerides) ordered by GP’s or medical specialists as
well as prescribed drugs, including lipid lowering drugs.
Design: A follow-up study of patients who had records
of lipid levels available and either started or did not start
treatment with lipid lowering drugs between January
1991 and December 2001. Included patients had at least
one baseline cholesterol measurement during the six
months prior to the initiation of lipid lowering drugs and
at least one cholesterol measurement after initiation. For
these patients, use of lipid lowering drugs and levels of
cholesterol were followed for a maximum period of ﬁve
years with goal attainment as endpoint. Goal attainment
was deﬁned as total cholesterol below 5.0mmol/l.
RESULTS: Our results indicate that only 30.2% of all
treated patients achieved goals in the ﬁrst year of treat-
ment. The percentage varied from 17.7% to 41.7%,
depending on dose and the prescribed statin. After the
introduction of new guidelines in 1998, which advised to
treat patients more aggressively, the percentage rose from
22% of those patients treated before 1998 to 42% for
those in whom treatment was initiated after 1998. CON-
CLUSIONS: Although results from this study indicate
that the selection of patients and the initial lipid lower-
ing treatment for this cohort are in line with the national
guidelines in the Netherlands, the percent of patients
achieving guideline recommended goal is low in real-life
even in patients treated with high dose statins.
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OBJECTIVE: To evaluate the effectiveness and cost-
effectiveness of the ABPM in the diagnostic of arterial
hypertension in our region during 5 years. METHODS:
Retrospective study of 1,845 registries of ABPM (1996 to
2000). Variables: age, sex, ABPM date, previous blood
pressure (BP) measured at home or at ofﬁce (OBP), pre-
vious diagnostic of hypertension, BP pre-ABPM, ﬁrst BP
with ABPM, day, night and 24 hours BP with ABPM and
later therapeutic changes and cardiovascular events. Sen-
sitivity (Se), speciﬁcity (Sp), positive (PPV) and negative
(NPV) predictive values were calculated. Avoided cardio-
vascular events, ABPM costs and costs by one avoided
cardiovascular event were also calculated using a sample
of control subjects with hypertension but without ABPM.
RESULTS: In the whole sample the values obtained 
for ABPM vs OBP were: Se = 76.4%; Sp = 75%; PPV =
95.6%; NPV = 30.7%. In the group of patients with
essential hypertension were 77.9%, 82.2%, 98.3%, and
21.6%. In patients with mild hypertension were 70.5%,
71.4%, 93.6%, and 29.1%. And for white-coat hyper-
tension were 71.4%, 100% 100% and 12.8%. A thera-
peutic change was indicated in 42.4% of patients with
essential hypertension, 100% of those with mild hyper-
tension and 40% of patients with white-coat hyperten-
sion, when hypertension was conﬁrmed. Therapeutic
changes were also indicated in patients with no conﬁr-
mation of the diagnostic: 42.8%, 16.7%, and 20%
respectively. The number of cardiovascular events in the
control group was 7.4%, in the patients with essential
hypertension 14.9%, in mild hypertension 0% and in
with white-coat hypertension was 10% (0% if therapeu-
tic change was prescribed). The cost for one avoided car-
diovascular event in the two latters was €563.11, and
taking into account the mean costs of one cardiovascular
event, it would be saved €3,420.96 for one avoided car-
diovascular event. CONCLUSIONS: ABPM is a good
cost-effectiveness method for mild and white-coat 
hypertension.
